Life Sciences

China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
June 26, 2017
In the last 60 years, $400 million invested over 23 federally funded cancer research trials added 3.34 million years to the lives of U.S. patients, writes John Wu in Innovation Files.
June 14, 2017
ITIF submitted comments to the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service on its proposed revisions to regulations governing crops improved through biotechnology.
June 14, 2017
ITIF submitted comments to the Food and Drug Administration on how they should regulate foods derived from gene-edited plants.
June 6, 2017
For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.
May 30, 2017
Pharmaceutical innovation accounted for 73 percent of the increase in life expectancy (approximately 1.73 years) in 30 developing and developed countries from 2000 to 2009, writes John Wu in Innovation Files.
March 21, 2017
Bipartisan collaboration on the Hill has proven scant in the opening weeks of the Trump era, but the opportunity to reauthorize the Prescription Drug User Fee Act provides a welcome occasion for bipartisan comity while extending legislation that has played a foundational role in underpinning U.S. life-sciences leadership and helping bring safe, innovative cures to patients faster, writes Stephen Ezell in Innovation Files.
February 27, 2017
PDUFA enables a safe, timely, and efficient process of drug evaluation while applying best practices in regulatory science that support America’s global leadership in biomedical innovation.
November 3, 2016
As Singapore continues its efforts to transform a small island nation into a global innovation hub, the innovation-enabling trade regime the Trans-Pacific Partnership fosters will benefit all industries but especially advanced technology ones, in areas such as life sciences and information technology, on which Singapore’s economy (like America’s) increasingly thrives, writes John Wu in Innovation Files.
November 2, 2016
Every additional year of market exclusivity given to a breakthrough compound increases the number of subsequent drugs approved in that class by between 18 and 25 percent—20 percent on average, writes John Wu in Innovation Files.
July 14, 2016
The UN high-level access to medicines panel must consider the complete range of factors impacting access to medicines, writes Stephen Ezell in Innovation Files.

Pages